163 related articles for article (PubMed ID: 37202241)
1. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study.
Kim JH; Lee H; Oh IS; Jeong HE; Bea S; Jang SH; Son H; Shin JY
J Microbiol Immunol Infect; 2023 Aug; 56(4):842-852. PubMed ID: 37202241
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
3. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
Putra ON; Yulistiani Y; Soedarsono S
Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917
[TBL] [Abstract][Full Text] [Related]
4. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
5. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
[TBL] [Abstract][Full Text] [Related]
11. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Auchynka V; Kumar AMV; Hurevich H; Sereda Y; Solodovnikova V; Katovich D; Setkina S; Yedilbayev A; Skrahin A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470081
[TBL] [Abstract][Full Text] [Related]
13. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
Olayanju O; Esmail A; Limberis J; Dheda K
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
[TBL] [Abstract][Full Text] [Related]
14. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis.
Ahmed SH; Haider H; Moeed A; Mahmood A; Shivani N; Shuja SH; Hayat J; Jamil B; Fatima R
Indian J Tuberc; 2024 Jan; 71(1):79-88. PubMed ID: 38296395
[TBL] [Abstract][Full Text] [Related]
16. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C; Khan U; Bastard M; Lachenal N; Coutisson S; Osso E; Ahmed S; Khan P; Franke MF; Rich ML; Varaine F; Melikyan N; Seung KJ; Adenov M; Adnan S; Danielyan N; Islam S; Janmohamed A; Karakozian H; Kamene Kimenye M; Kirakosyan O; Kholikulov B; Krisnanda A; Kumsa A; Leblanc G; Lecca L; Nkuebe M; Mamsa S; Padayachee S; Thit P; Mitnick CD; Huerga H
Clin Infect Dis; 2022 Sep; 75(6):1006-1013. PubMed ID: 35028659
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
18. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
19. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
Holmgaard FB; Guglielmetti L; Lillebaek T; Andersen ÅB; Wejse C; Dahl VN
Clin Infect Dis; 2023 Apr; 76(7):1328-1337. PubMed ID: 36331978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
